Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$1.7B
95M shares
52-week range
$7.40 – $21.39
74% from low
Sector
SERVICES-MEDICAL LABORATORIES
Exchange
NASDAQ
CS
Fortrea is a global, late-stage contract research organization that provides comprehensive phase 1 through phase 4 clinical trial management, clinical pharmacology, and patient access solutions. The company works with emerging and large biopharma, medical device, and diagnostic companies to run their clinical trials as a functional-service provider, full-service provider, and offers hybrid trials. In 2023, Fortrea was formed as an independent, publicly traded company after Labcorp spun off its clinical development business, which it acquired via its purchase of Covance in 2015 for $6.1 billion.
www.fortrea.comNo one on the platform currently holds FTRE.
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 1,432,709 | $13.5M |
No one on the platform has traded FTRE yet.
Click to see transaction details on SEC.gov. Form 4s cover trades by officers, directors, and 10%+ owners, due within 2 business days of the trade.
$FTRE Something up here. Price bouncing all over since earnings.
View on StockTwits ↗$FTRE Pretty harsh dump at the open. XBI up so what's the reason?
View on StockTwits ↗https://www.marketbeat.com/earnings/reports/2026-7-29-fortrea-holdings-inc-stock/ $FTRE Fortrea Earnings Transcript
View on StockTwits ↗$FTRE Q2 '26 Earnings Results & Recap • Reported GAAP EPS of -$0.14 up 96.62% YoY • Reported revenue of $678.2M down -4.52% YoY • Fortrea increased its full-year 2026 guidance, now targeting revenues in the range of $2,620 million to $2,690 million and adjusted EBITDA in the range of $205 million to $220 million.
View on StockTwits ↗$FTRE undiscovered breakout with 201 watchers
View on StockTwits ↗$FTRE Fortrea stock, nice close and narrow range breakout from Stocks to Watch at https://stockconsultant.com/?FTRE Breakout trade CONFIRMED breakout above 18.45 Target: 21.14, 14.4% Stop: 17.55 Loss: 5.1% P/L ratio: 2.8 : 1 - Good BULLISH [Timing] Strong bullish 3 day candlestick pattern. [Timing] CONFIRMED breakout above 18.45, no resistance in area just above. BEARISH [Positioning] Intermediate trend bearish, Unsustainable uptrend, may turn sideways.
View on StockTwits ↗$FTRE Fortrea stock with a top of range bull flag breakout at https://stockconsultant.com/?FTRE Breakout trade CONFIRMED breakout above 18.3 Target: 21.19, 15.8% Stop: 17.36 Loss: 5.2% P/L ratio: 3 : 1 - Good BULLISH [Timing] Strong bullish 3 day candlestick pattern. [Timing] CONFIRMED breakout above 18.3, no resistance in area just above. BEARISH [Positioning] 1 Day Price change strong up, may pause [Positioning] Short term typical rally, rally may start to slow. [Positioning] Overbought, odds favor short trades. [Positioning] Intermediate trend bearish, Unsustainable uptrend, may turn sideways.
View on StockTwits ↗$FTRE this thing was dragged down by LabCorps and then spun off with a ton of debt. Their balance sheet is significantly improved and once the CRO market rebounds in a few years, this thing will double. With a current valuation below annual revenue, it’s a buy and hold for the long term based on projected earnings growth opportunities
View on StockTwits ↗$FTRE https://anachart.com/wp-content/uploads/2026/06/1782298867_soc-img.jpg
View on StockTwits ↗$CRM my life experience the hedge funds and market players will drop something to extreme extreme lows if they believe it’s a profitable opportunity I’ve seen it with $JXN $FTRE
View on StockTwits ↗$FTRE haven't followed this. Anybody know why the earnings expectations are lower than 2025 ?
View on StockTwits ↗$FTRE (weekly/daily) Nice looking flaggy pennant thingy on the daily
View on StockTwits ↗Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2026 | $2.7B | -2.4% | $0.84 | $0.77–$0.98 | 21.2× | 7 |
| 2027 | $2.7B | +3.0% | $1.06 | $0.87–$1.26 | 16.7× | 7 |
| 2028 | $2.9B | +4.3% | $1.33 | $-31.31–$39.31 | 13.4× | 4 |
| 2029 | $3.0B | +5.5% | $1.73 | $1.71–$1.76 | 10.3× | 1 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 4 of the last 8 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2026-07-29 | $0.18 | $0.23 | +27.5% |
| 2026-05-05 | $0.03 | $0.16 | +433.3% |
| 2026-02-26 | $0.16 | $0.09 | -43.8% |
| 2025-11-05 | $0.16 | $0.12 | -25.0% |
| 2025-08-06 | $0.06 | $0.19 | +216.7% |
| 2025-05-12 | $-0.07 | $0.02 | +128.6% |
| 2025-03-03 | $0.36 | $0.18 | -50.0% |
| 2024-11-08 | $0.27 |
| $0.23 |
| -14.8% |
| $1.1B |
| — |
| KURAKura Oncology, Inc. | $10.09 | +1.51% | $896M | — |
| MRVIMaravai LifeSciences Holdings, Inc. | $5.78 | +0.00% | $1.6B | — |
Source: Financial Modeling Prep · peers by sector/industry